Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...

Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating ...

Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Robert W. Baird from $117.00 to $73 ...

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage ...

US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an independent review insisted it would likely fail to meet its endpoints. An ...

Richard Heinberg, a senior fellow with the Post Carbon Institute in Santa Rosa, will be the featured speaker at a weekend ...

Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal. Shares of the ...

Truist lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares. The firm is removing ...

FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of countless patients with rare diseases by modernizing and streamlining the FDA ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $132.2, a high estimate of $175.00, and a low estimate of $105.00. This current average represents a 2.07% ...